The Sierra Leone government will introduce a hepatitis B birth-dose vaccine as part of its routine immunisation programme starting 20 November 2026. This initiative aims to prevent infections among newborns and reduce the transmission of the virus from mothers to their children.
The announcement was made during a media event by the Ministry of Health on 18 November, attended by health officials, representatives from WHO, UNICEF, and Gavi, as well as journalists. The vaccine will be given to newborns within the first 24 hours of life at no cost in government health facilities across all 16 districts of Sierra Leone.
Deputy Minister of Health Professor Charles Senesie highlighted the concerning prevalence of hepatitis B in the country, which stands at 13.8%, affecting approximately 1.1 million people. The highest rates are found among those aged 30 to 44, and five districts account for around half of the cases. Hepatitis B can lead to severe liver complications, especially if contracted early in life. Up to 90% of infants infected in their first year may develop chronic hepatitis B.
The introduction of the vaccine marks a significant step in safeguarding children from the virus at an early age. The WHO’s Dr Thompson Igbu lauded this effort, noting that administering the vaccine shortly after birth is key to preventing mother-to-child transmission. WHO also emphasised the need to enhance maternal and newborn healthcare to ensure timely immunisations.
UNICEF and Gavi are collaborating with the government to support vaccine procurement and education efforts. Gavi has provided over $240,000 towards vaccine procurement, while the government contributes about $60,000 for additional support. Each year, Sierra Leone sees around 400,000 births, with the aim of vaccinating approximately 360,000 newborns through this initiative.
The hepatitis B birth dose is a single injection recommended within 24 hours of delivery. Babies missing this timeframe should still be vaccinated as soon as possible, ideally within 72 hours. All newborns, including those born prematurely or at home, are eligible for the vaccine.
The Ministry of Health assures parents that the vaccine is safe, supported by WHO recommendations. Minor side effects may occur, such as redness at the injection site or a slight fever. Parents are advised to report any concerns to local health facilities.
To prepare for the rollout, the Ministry has engaged in community outreach, trained healthcare workers, and improved maternity vaccination services. Mobile network operators are also assisting in disseminating information about the vaccine. The introduction of the hepatitis B vaccine is expected to enhance Sierra Leone’s immunisation efforts and combat hepatitis B-related health issues, including liver cancer, in the long term.